Table 4 Results of socioeconomic burden estimation of two multidrug-resistant organisms’ pneumonia.
MRAB-P | MRPA-P | |||
|---|---|---|---|---|
Minimum | Maximum | Minimum | Maximum | |
Number of cases in 2017 (N) | 1309 | 2483 | 339 | 644 |
Hospital cost differences (C) ($) (95% CI) | 42,203 (34,102–50,303) | 35,556 (20,423–50,689) | ||
LOS differences (L) (days) (95% CI) | 49 (39–58) | 45 (27–63) | ||
90 day mortality rate (95% CI) | 37.0% (28–46%) | 37.0% (28–46%) | 39.3% (21–57%) | 39.3% (21–57%) |
Total hospital cost (NXC) ($) (95% CI) | 55,243,476 (44,640,002–65,846,949) | 104,789,573 (84,676,185–124,902,960) | 12,053,593 (6,923,544–17,183,642) | 22,898,271 (13,152,692–32,643,851) |
Excess cost of caregiver use ($) (95% CI) | 2869.4 (2283.8–3396.4) | 2635.2 (1581.1–3689.2) | ||
Total cost of excess caregiver use ($) (95% CI) | 3,756,005 (2,983,473–4,445,883) | 7,124,644 (5,670,635–8,443,252) | 893,333 (535,986–1,250,635) | 1,697,069 (1,018,216–2,375,838) |
Estimated number of deaths in 1 year (95% CI) | 485 (365–604) | 920 (693–1145) | 133 (72–195) | 253 (137–370) |
Productivity loss due to mortality ($) (95% CI) | 5,550,242 (4,178,541–6,906,609) | 10,619,368 (7,994,704–13,214,252) | 2,294,957 (1,240,619–3,357,129) | 4,398,668 (2,374,665–6,425,870) |
Total socioeconomic burden ($) (95% CI) | 64,549,723 (51,802,016–77,199,441) | 122,533,585 (98,341,524–146,560,464) | 15,241,883 (8,700,149–21,791,406) | 28,994,008 (16.545,573–41,445,559) |
